Information Provided By: 
Fly News Breaks for September 24, 2015
HRTX, PCRX
Sep 24, 2015 | 06:02 EDT
Barclays analyst Douglas Tsao views yesterday's selloff in shares of Pacira Pharmaceuticals (PCRX) as an overreaction. Heron Therapeutics (HRTX) tried to make the case that its product has a superior profile to Pacira's Exparel, but its data "raised several questions that could affect its path to market," Tsao tells investors in a research note. The analyst remains confident in Exparel's market position over the long-term and keeps an Overweight rating on Pacira with am $85 price target.
News For PCRX;HRTX From the Last 2 Days
HRTX
Apr 25, 2024 | 10:38 EDT
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here
